I just looked at the November presentation and the third clinical responder in the 202 trial also had less severe disease, giving 3 out of 10 responders. If the 202 results are any guide we should be cautiously hopeful of a result greater than 30% clinical responders in the 201 trial, considering all 201 patients have less severe disease. In knowing this I'm surprised the price action in the US is still negative and flat here. On what is known from the 202 trial so far, you would think the odds would favor a positive outcome in the 201 trial.There's no guarantees of that but it does look that way. We will know a lot more in 8 weeks.
I just looked at the November presentation and the third...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $60.81K | 5.737M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 16255465 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1643984 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |